Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Price Discount Paves The Way For NICE To Clear GSK’s Revolade

This article was originally published in The Pink Sheet Daily

Executive Summary

U.K. drug cost watchdog NICE has cleared Glaxo’s Revolade and Alcon's Jetrea but rejected Lilly's Alimta as maintenance therapy in a subgroup of lung cancer patients.


Related Content

NICE Clears Alimera’s Iluvien For DME In Patients With Artificial Lens
End-Of-Life-Considerations Fail To Save Lilly’s Alimta For NSCLC At NICE
With Discount In Place, NICE Gives Nod To Amgen's Nplate For Bleeding Disorder
NICE Rejects Revolade For Bleeding Disorders; GSK Considering Its Options
Will Maintenance Sell In NSCLC? Experts Weigh Costs Against Benefits
U.K.'s Controversial NICE Suspends Publication Of Guidances Until After General Election


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts